Trial Profile
A phase 2 trial of PNT2258 in solid tumors
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Rosomidnar (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 09 Jan 2017 According to a Sierra Oncology media release, this trial was originally conducted by ProNAi Therapeutics, Inc. but later on this company's name changed to Sierra Oncology.
- 25 Aug 2015 New trial record
- 21 Aug 2015 According to ProNAi therapeutics media release, company is planning to initiate this trial in 2016.